undamentalytics Newsletter
Sign in

Karyopharm Therapeutics Inc. balance sheet

At the end of fiscal 2025, Karyopharm Therapeutics Inc. had total assets of $108m, total liabilities of $401m and shareholders' equity of −$293m. It held $60.5m in cash against $94.8m of debt: net debt of $34.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents701561515850691181298619013552626155
Receivables————————813224727312630
Inventory————————03443544
Total current assets—1158208178132148335279277276350234156103106
Total assets—1158220215180180341295313305358240164108111
Accounts payable—126456414233548
Deferred revenue (current)—00———22920——————
Total current liabilities—23121516494746607466699292134
Long-term debt———————1031101181691701710——
Total debt0000000103110118193170171959585
Total liabilities——314171851158245263385375377350401441
Shareholders' equity−13−281552071981621291835051−80−17−136−186−293−330
Net debt (negative = net cash)−7−0−156−151−58−50−69−15−1932335119323430
Shares outstanding———————————————23m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BEAM vs KPTIAGEN vs KPTIIBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Karyopharm Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Karyopharm Therapeutics Inc.